 |
|
Sustained uremic toxin control improves renal and cardiovascular outcomes in patients with advanced renal dysfunction:
Ran-hui Cha, Shin Wook Kang, Cheol Whee Park, Dae Ryong Cha, Ki Young Na, Sung Gyun Kim, Sun Ae Yoon, Sejoong Kim, Sang Youb Han, Jung Hwan Park, Jae Hyun Chang, Chun Soo Lim, Yon Su Kim
Kidney Res Clin Pract. 2017;36(1):68-78. Published online 2017 Mar 31 DOI: https://doi.org/10.23876/j.krcp.2017.36.1.68
|
|
Citations to this article as recorded by
 Relationship between urinary potassium excretion, serum potassium levels and cardiac injury in non-dialysis chronic kidney disease: KoreaN cohort study for Outcome in patients With Chronic Kidney Disease (KNOW-CKD)
Hyang Ki Min, Su Ah Sung, Ji Yong Jung, Yun Kyu Oh, Kyu Beck Lee, Sue K. Park, Kook-Hwan Oh, Curie Ahn, Sung Woo Lee
British Journal of Nutrition.2024; 131(3): 429. CrossRef Design and rationale for an open-label, randomized, controlled pilot trial to evaluate the changes in blood uremic toxins in patients with chronic kidney disease by dietary therapy with sake lees
Toshiaki Tokumaru, Tadashi Toyama, Yusuke Nakade, Hisayuki Ogura, Megumi Oshima, Shiori Nakagawa, Motoe Furuichi, Shinji Kitajima, Norihiko Sakai, Miho Shimizu, Yasunori Iwata, Takashi Wada
Clinical and Experimental Nephrology.2024;[Epub] CrossRef AST-120 improved uremic pruritus by lowering indoxyl sulfate and inflammatory cytokines in hemodialysis patients
Chia-Chao Wu, Ya-Chung Tian, Chien-Lin Lu, Ming-Ju Wu, Paik-Seong Lim, Yi-Wen Chiu, Ko-Lin Kuo, Shou-Hsuan Liu, Yu-Ching Chou, Chien-An Sun, Yi-Chou Hou, Kuo-Cheng Lu
Aging.2024;[Epub] CrossRef Association between prevalence of laxative use and history of bone fractures and cardiovascular diseases in patients with chronic kidney disease: the Fukuoka Kidney disease Registry (FKR) study
Shunsuke Yamada, Shigeru Tanaka, Hokuto Arase, Hiroto Hiyamuta, Hiromasa Kitamura, Masanori Tokumoto, Koji Mitsuiki, Kazuhiko Tsuruya, Takanari Kitazono, Toshiaki Nakano
Clinical and Experimental Nephrology.2023; 27(2): 151. CrossRef Obstructive nephropathy and molecular pathophysiology of renal interstitial fibrosis
Rikke Nørregaard, Henricus A. M. Mutsaers, Jørgen Frøkiær, Tae-Hwan Kwon
Physiological Reviews.2023; 103(4): 2847. CrossRef Serum VEGF-D level is correlated with renal dysfunction and proteinuria in patients with diabetic chronic kidney disease
Thi Thuy Uyen Nguyen, Hyeongwan Kim, Yoon Jung Chae, Jong Hwan Jung, Won Kim
Medicine.2022; 101(7): e28804. CrossRef Administration of the probiotic Lactiplantibacillus paraplantarum is effective in controlling hyperphosphatemia in 5/6 nephrectomy rat model
Sung Jin Moon, Junsang Hwang, Woo Kyung Kang, Jeong-Pin Ahn, Hyo Jin Kim
Life Sciences.2022; 306: 120856. CrossRef Oral Absorbent AST-120 Is Associated with Compositional and Functional Adaptations of Gut Microbiota and Modification of Serum Short and Medium-Chain Fatty Acids in Advanced CKD Patients
Cheng-Kai Hsu, Shih-Chi Su, Lun-Ching Chang, Kai-Jie Yang, Chin-Chan Lee, Heng-Jung Hsu, Yih-Ting Chen, Chiao-Yin Sun, I-Wen Wu
Biomedicines.2022; 10(9): 2234. CrossRef The Medium Cut-Off Membrane Does Not Lower Protein-Bound Uremic Toxins
Yang Gyun Kim, Sang Ho Lee, Su Woong Jung, Gun Tae Jung, Hyun Ji Lim, Kwang Pyo Kim, Young-Il Jo, KyuBok Jin, Ju Young Moon
Toxins.2022; 14(11): 779. CrossRef Intestinal Chelators, Sorbants, and Gut-Derived Uremic Toxins
Solène M. Laville, Ziad A. Massy, Said Kamel, Jean Marc Chillon, Gabriel Choukroun, Sophie Liabeuf
Toxins.2021; 13(2): 91. CrossRef Challenges of reducing protein-bound uremic toxin levels in chronic kidney disease and end stage renal disease
Mónica Faria, Maria Norberta de Pinho
Translational Research.2021; 229: 115. CrossRef Comparison of Different Types of Oral Adsorbent Therapy in Patients with Chronic Kidney Disease: A Multicenter, Randomized, Phase IV Clinical Trial
Youn Kyung Kee, Sang Youb Han, Duk-Hee Kang, Jung Woo Noh, Kyung Hwan Jeong, Gheun-Ho Kim, Yang Wook Kim, Beom Seok Kim
Yonsei Medical Journal.2021; 62(1): 41. CrossRef Reduction of protein‐bound uraemic toxins in plasma of chronic renal failure patients: A systematic review
V. Saar‐Kovrov, W. Zidek, S. Orth‐Alampour, D. Fliser, V. Jankowski, E. A. L. Biessen, J. Jankowski
Journal of Internal Medicine.2021; 290(3): 499. CrossRef Effect of Renamezin upon attenuation of renal function decline in pre-dialysis chronic kidney disease patients: 24-week prospective observational cohort study
Hayne Cho Park, AJin Cho, Do Hyoung Kim, Kyu-sang Yun, Juhee Kim, Eun Young Lee, Sang Kyung Jo, So-Young Lee, Kum Hyun Han, Yoon Kyung Chang, Dong-Jin Oh, Young-Ki Lee, Hayato Iwase
PLOS ONE.2021; 16(6): e0252186. CrossRef Efficacy of AST-120 for Patients With Chronic Kidney Disease: A Network Meta-Analysis of Randomized Controlled Trials
Pei-Yu Su, Ya-Han Lee, Li-Na Kuo, Yen-Cheng Chen, Chiehfeng Chen, Yi-No Kang, Elizabeth H. Chang
Frontiers in Pharmacology.2021;[Epub] CrossRef Pharmacological Actions of Indoxyl Sulfate and AST-120 That Should Be Recognized for the Strategic Treatment of Patients with Chronic Kidney Disease Daisuke Nagata, Hiromichi Yoshizawa
International Journal of Nephrology and Renovascular Disease.2020; Volume 13: 359. CrossRef The clinical impact of gut microbiota in chronic kidney disease
So Mi Kim, Il han Song
The Korean Journal of Internal Medicine.2020; 35(6): 1305. CrossRef Protein-Bound Uremic Toxins in Hemodialysis Patients Relate to Residual Kidney Function, Are Not Influenced by Convective Transport, and Do Not Relate to Outcome
Maaike K. van Gelder, Igor R. Middel, Robin W. M. Vernooij, Michiel L. Bots, Marianne C. Verhaar, Rosalinde Masereeuw, Muriel P. Grooteman, Menso J. Nubé, M. A. van den Dorpel, Peter J. Blankestijn, Maarten B. Rookmaaker, Karin G.F. Gerritsen
Toxins.2020; 12(4): 234. CrossRef Review of the efficacy of AST-120 (KREMEZIN®) on renal function in chronic kidney disease patients
Mayumi Asai, Sei Kumakura, Mami Kikuchi
Renal Failure.2019; 41(1): 47. CrossRef Framingham risk score and risk of incident chronic kidney disease: A community-based prospective cohort study
Changhyun Lee, Hae-Ryong Yun, Young Su Joo, Sangmi Lee, Joohwan Kim, Ki Heon Nam, Jong Hyun Jhee, Jung Tak Park, Tae-Hyun Yoo, Shin-Wook Kang, Seung Hyeok Han
Kidney Research and Clinical Practice.2019; 38(1): 49. CrossRef Evaluation of Food and Spherical Carbon Adsorbent Effects on the Pharmacokinetics of Roxadustat in Healthy Nonelderly Adult Male Japanese Subjects
Tomohisa Shibata, Yuki Nomura, Akitsugu Takada, Mai Ueno, Masataka Katashima, Rie Yazawa, Kenichi Furihata
Clinical Pharmacology in Drug Development.2019; 8(3): 304. CrossRef Prediction of Patients Who Can Benefit from Oral Intestinal Sorbent AST-120
Ran-hui Cha
Journal of Korean Medical Science.2019;[Epub] CrossRef Effects and Safety of an Oral Adsorbent on Chronic Kidney Disease Progression: A Systematic Review and Meta-Analysis
Ying-Chun Chen, Mei-Yi Wu, Ping-Jen Hu, Tzu-Ting Chen, Wan-Chen Shen, Wei-Chiao Chang, Mai-Szu Wu
Journal of Clinical Medicine.2019; 8(10): 1718. CrossRef Molecular mechanisms underlying uremic toxin-related systemic disorders in chronic kidney disease: focused on β2-microglobulin-related amyloidosis and indoxyl sulfate-induced atherosclerosis—Oshima Award Address 2016
Suguru Yamamoto
Clinical and Experimental Nephrology.2019; 23(2): 151. CrossRef Deleting Death and Dialysis: Conservative Care of Cardio-Vascular Risk and Kidney Function Loss in Chronic Kidney Disease (CKD)
Raymond Vanholder, Steven Van Laecke, Griet Glorieux, Francis Verbeke, Esmeralda Castillo-Rodriguez, Alberto Ortiz
Toxins.2018; 10(6): 237. CrossRef Changes in obese metabolic phenotypes over time and risk of incident chronic kidney disease
Ki Heon Nam, Hae‐Ryong Yun, Young Su Joo, Joohwan Kim, Sangmi Lee, Changhyun Lee, Kyoung Sook Park, Jung Tak Park, Tae‐Ik Chang, Ea Wha Kang, Tae‐Hyun Yoo, Shin‐Wook Kang, Seung Hyeok Han
Diabetes, Obesity and Metabolism.2018; 20(12): 2778. CrossRef Risk factors for progression of chronic kidney disease in the EPPIC trials and the effect of AST-120
Gerald Schulman, Tomas Berl, Gerald J. Beck, Giuseppe Remuzzi, Eberhard Ritz, Miho Shimizu, Mami Kikuchi, Yuko Shobu
Clinical and Experimental Nephrology.2018; 22(2): 299. CrossRef Role of Uremic Toxins for Kidney, Cardiovascular, and Bone Dysfunction
Hideki Fujii, Shunsuke Goto, Masafumi Fukagawa
Toxins.2018; 10(5): 202. CrossRef Cardiovascular risk in chronic kidney disease: what is new in the pathogenesis and treatment?
Angelika Bazyluk, Jolanta Malyszko, Edyta Zbroch
Postgraduate Medicine.2018; 130(5): 461. CrossRef Impacts of Indoxyl Sulfate and p-Cresol Sulfate on Chronic Kidney Disease and Mitigating Effects of AST-120
Wen-Chih Liu, Yasuhiko Tomino, Kuo-Cheng Lu
Toxins.2018; 10(9): 367. CrossRef Importance of AST-120 (Kremezin®) Adherence in a Chronic Kidney Disease Patient with Diabetes
Yasuhiko Tomino, Atsuko Hisada-Urita, Takuto Seki, Tomonari Watanabe, Reo Kanda, Toshimasa Takahashi
Case Reports in Nephrology and Dialysis.2018; 8(2): 107. CrossRef
|